These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

668 related items for PubMed ID: 9400997

  • 1. ErbB kinases and NDF signaling in human prostate cancer cells.
    Grasso AW, Wen D, Miller CM, Rhim JS, Pretlow TG, Kung HJ.
    Oncogene; 1997 Nov 27; 15(22):2705-16. PubMed ID: 9400997
    [Abstract] [Full Text] [Related]

  • 2. NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways.
    Daly JM, Olayioye MA, Wong AM, Neve R, Lane HA, Maurer FG, Hynes NE.
    Oncogene; 1999 Jun 10; 18(23):3440-51. PubMed ID: 10376522
    [Abstract] [Full Text] [Related]

  • 3. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
    Lyne JC, Melhem MF, Finley GG, Wen D, Liu N, Deng DH, Salup R.
    Cancer J Sci Am; 1997 Jun 10; 3(1):21-30. PubMed ID: 9072304
    [Abstract] [Full Text] [Related]

  • 4. Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors.
    Alimandi M, Wang LM, Bottaro D, Lee CC, Kuo A, Frankel M, Fedi P, Tang C, Lippman M, Pierce JH.
    EMBO J; 1997 Sep 15; 16(18):5608-17. PubMed ID: 9312020
    [Abstract] [Full Text] [Related]

  • 5. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
    Ram TG, Ethier SP.
    Cell Growth Differ; 1996 May 15; 7(5):551-61. PubMed ID: 8732665
    [Abstract] [Full Text] [Related]

  • 6. Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase.
    Tan M, Grijalva R, Yu D.
    Cancer Res; 1999 Apr 01; 59(7):1620-5. PubMed ID: 10197638
    [Abstract] [Full Text] [Related]

  • 7. Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells.
    Bacus SS, Yarden Y, Oren M, Chin DM, Lyass L, Zelnick CR, Kazarov A, Toyofuku W, Gray-Bablin J, Beerli RR, Hynes NE, Nikiforov M, Haffner R, Gudkov A, Keyomarsi K.
    Oncogene; 1996 Jun 20; 12(12):2535-47. PubMed ID: 8700512
    [Abstract] [Full Text] [Related]

  • 8. Role of TGF alpha stimulation of the ERK, PI3 kinase and PLC gamma pathways in ovarian cancer growth and migration.
    Sewell JM, Smyth JF, Langdon SP.
    Exp Cell Res; 2005 Mar 10; 304(1):305-16. PubMed ID: 15707595
    [Abstract] [Full Text] [Related]

  • 9. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.
    Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, Di Fiore PP, Kraus MH.
    Oncogene; 1995 May 04; 10(9):1813-21. PubMed ID: 7538656
    [Abstract] [Full Text] [Related]

  • 10. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB, Hynes NE, Lane HA.
    Cancer Res; 2002 Jun 01; 62(11):3151-8. PubMed ID: 12036928
    [Abstract] [Full Text] [Related]

  • 11. The phosphatidylinositol 3'-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells.
    Lin J, Adam RM, Santiestevan E, Freeman MR.
    Cancer Res; 1999 Jun 15; 59(12):2891-7. PubMed ID: 10383151
    [Abstract] [Full Text] [Related]

  • 12. Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells.
    Daly JM, Jannot CB, Beerli RR, Graus-Porta D, Maurer FG, Hynes NE.
    Cancer Res; 1997 Sep 01; 57(17):3804-11. PubMed ID: 9288791
    [Abstract] [Full Text] [Related]

  • 13. Neu differentiation factor/heregulin modulates growth and differentiation of HC11 mammary epithelial cells.
    Marte BM, Jeschke M, Graus-Porta D, Taverna D, Hofer P, Groner B, Yarden Y, Hynes NE.
    Mol Endocrinol; 1995 Jan 01; 9(1):14-23. PubMed ID: 7760847
    [Abstract] [Full Text] [Related]

  • 14. Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes.
    Amundadottir LT, Leder P.
    Oncogene; 1998 Feb 12; 16(6):737-46. PubMed ID: 9488037
    [Abstract] [Full Text] [Related]

  • 15. Regulation of cyclooxygenase-2 pathway by HER2 receptor.
    Vadlamudi R, Mandal M, Adam L, Steinbach G, Mendelsohn J, Kumar R.
    Oncogene; 1999 Jan 14; 18(2):305-14. PubMed ID: 9927187
    [Abstract] [Full Text] [Related]

  • 16. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.
    Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ, Seger R, Hynes NE, Yarden Y.
    EMBO J; 1996 Jan 15; 15(2):254-64. PubMed ID: 8617201
    [Abstract] [Full Text] [Related]

  • 17. A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells.
    Zi X, Grasso AW, Kung HJ, Agarwal R.
    Cancer Res; 1998 May 01; 58(9):1920-9. PubMed ID: 9581834
    [Abstract] [Full Text] [Related]

  • 18. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.
    Graus-Porta D, Beerli RR, Daly JM, Hynes NE.
    EMBO J; 1997 Apr 01; 16(7):1647-55. PubMed ID: 9130710
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of transforming growth factor alpha (TGF-alpha)-mediated growth effects in ovarian cancer cell lines by a tyrosine kinase inhibitor ZM 252868.
    Simpson BJ, Bartlett JM, Macleod KG, Rabiasz G, Miller EP, Rae AL, Gordge P, Leake RE, Miller WR, Smyth J, Langdon SP.
    Br J Cancer; 1999 Mar 01; 79(7-8):1098-103. PubMed ID: 10098742
    [Abstract] [Full Text] [Related]

  • 20. Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways.
    Park JI, Lee MG, Cho K, Park BJ, Chae KS, Byun DS, Ryu BK, Park YK, Chi SG.
    Oncogene; 2003 Jul 10; 22(28):4314-32. PubMed ID: 12853969
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.